CASE REPORT

Can bone marrow-derived mesenchymal stem cells change liver volume?: A case report
Kwangmin Kim,*†‡ , In Sik Shin,*‡ Hui-Jae Bang,*‡ Sanghyun An,*‡ Gaesung Ha,*‡ Hyun Soo Kim,*‡ and Keum Seok Bae*†‡

*Department of Surgery, Yonsei University Wonju College of Medicine, †Trauma Center, ‡Wonju Severance Surgical Research Group, Wonju Severance Christian Hospital, Wonju, ‡Pharmicell Co., Ltd., Sungnam and Kim’s Stem Cell Clinic, Seoul, South Korea

Key words
computed tomography, liver cirrhosis, liver volume, mesenchymal stem cell.

Accepted for publication 18 November 2020.

Correspondence
Keum Seok Bae, Department of Surgery, Yonsei University Wonju College of Medicine, 20 Ilsan-ro, Wonju-si, Wonju, Gangwon-do 26426, South Korea.
Email: bksgs@yonsei.ac.kr

Declaration of conflict of interest: None.

Abstract
Several studies have described the effectiveness of mesenchymal stem cell (MSC) transplantation in patients with liver cirrhosis (LC). However, in the majority, biochemical tests, clinical features, and pathologic results were used rather than radiologic tests to compare treatment outcomes. A 57-year-old male visited a stem cell clinic with a diagnosis of LC attributed to hepatitis B virus. This patient took tenofovir and diuretics at the initial presentation and was administered bone marrow-derived MSCs twice via hepatic intra-arterial infusion. Subsequently, the patient’s clinical symptoms and biochemical tests (aspartate aminotransferase, alanine aminotransferase, albumin, total bilirubin, international normalized ratio, creatinine, alpha-fetoprotein) improved. Computed tomography findings showed loss of ascites, reduced nodularity, and especially increased liver volume, which suggested that MSCs have meaningful effects on liver volume, as well as improving liver function.

Introduction
Liver cirrhosis (LC) is the end result of long-term liver damage, and its associated morbidities impose significant health-care burdens. Liver transplantation is the only definitive therapeutic option for these patients. However, the paucity of donors, rejection, and the high cost are hindering factors. In addition, lifelong immunosuppression is a worrisome issue. Cell-based regenerative therapies, particularly adult stem cell-based therapies, are evolving as viable clinical alternatives.1 Indeed, many studies have reported the effectiveness of mesenchymal stem cell (MSC) transplantation in patients with LC.2–4 However, in most of these studies, biochemical tests, clinical features, and pathologic results were used rather than radiologic tests to compare treatment outcomes. This case report demonstrates the effectiveness of MSC infusion based on computed tomography (CT) findings of an increase in liver volume in a patient with hepatitis B virus (HBV)-associated LC. The MSCs were obtained from bone marrow and administered via hepatic artery.

Case report
A 57-year-old Korean man presented at a stem cell clinic with a diagnosis of HBV-associated LC with abdominal distension and peripheral pitting edema. Eight weeks before this visit, the patient was admitted to a local medical center with the same symptoms, and biochemical tests and radiologic findings resulted in a diagnosis of LC. At this presentation, the symptoms had not improved despite the patient being on tenofovir and diuretics (spironolactone, furosemide) for 8 weeks, and the patient had Child-Pugh (CP) grade B (score 9) disease with gross ascites, spider angioma, umbilical hernia, and peripheral pitting edema but no overt jaundice. The liver was hardly palpated in the epigastric area. Endoscopy showed esophageal varix and CT revealed liver shrinkage, a huge amount of ascites, and splenomegaly.

Following the provision of informed patient consent, MSC transplantation was conducted on two separate occasions. A total of 20–25 milliliters (mean ± SD: 23.1 ± 11.5 mL) of bone marrow (BM) aspirates were obtained under local anesthesia from the posterior iliac crest during the visit before treatment. All manufacturing and product-testing procedures for the generation of clinical-grade autologous MSCs were conducted in accordance with good manufacturing practice (Pharmicell Company Limited, Sungnam, Korea). Mononuclear cells were separated from BM by density gradient centrifugation (HISTOPAQUE-1077; Sigma-Aldrich, St. Louis, MO, USA) and washed with phosphate-buffered saline (PBS). Cells were resuspended in Dulbecco’s modified Eagle’s medium-low glucose (DMEM; Gibco, Grand Island, NY, USA) containing 10% fetal bovine serum (Gibco) and 100 U/mL penicillin/100 μg/mL streptomycin (Gibco). Cells were then plated at 2–3 × 10^5 cells/cm² into 75-cm² flasks and maintained in a humidified 5% CO₂ atmosphere at 37°C for 5–7 days, after which nonadherent cells were removed by replacing the medium. Cells were then cultured for another 2–3 days, and when near confluent (70–80%), adherent cells were detached using trypsin containing ethylenediamine tetraacetic acid (EDTA; Gibco) and then replated at 4–5 × 10^3
cells/cm² in 175-cm² flasks. Cells were serially subcultured to passage 4 or 5 for infusion (4.4 ± 0.5 passages [mean ± SD]).

On the day of injection, MSCs were harvested using trypsin/EDTA, washed twice with PBS and once with saline solution, and then resuspended at a final concentration of $5 \times 10^6$ cells/mL in 10 mL of saline solution. The clinical criteria used were: viability $>$80% and the absence of microbial contamination (bacteria, fungus, virus, or mycoplasma) when tested 3–4 days before administration and in the presence of CD73 and CD105 in $>$90% of cells by flow cytometry. Cells ($5 \times 10^7$ in 10 mL of saline) were injected via the right hepatic artery using a coaxial angiographic catheter (Boston

Table 1  Biochemical parameters and Child-Pugh scores of our liver cirrhosis patient

|                | Baseline | Week 0    | Week 4 | Week 12 | Week 16 | Week 24 | Week 80 |
|----------------|----------|-----------|--------|---------|---------|---------|---------|
| AST (U/L)      | 83       | 55        | 49     |         | 38      | 35      |         |
| ALT (U/L)      | 42       | 35        | 31     |         | 23      | 25      |         |
| Albumin (g/dL) | 2.56     | 3.25      | 3.76   |         | 4.27    | 4.2     |         |
| Total Bilirubin (mg/dL) | 1.96 | 1.17      | 1      |         | 1.5     | 1.4     |         |
| INR            | 1.38     | 1.3       | 1.3    |         | 1.14    | 1.01    |         |
| Platelet (1000/µL) | 93.1 | 93.9      | 92.1   | 95.4    | 78      |         |         |
| Creatinine (mg/dL) | 1.23 | 0.94      | 0.99   |         | 1.02    | 1       |         |
| αFP (ng/mL)    | 212.3    | 33.9      | 18.9   |         | 16.4    | 10.93   |         |
| Quantitative HBV DNA PCR (IU/mL) | 390 000 | 618       | 380    |         | 33.2    |         |         |
| CP score       | 9        | 7         | 5      |         | 5       | 5       |         |

αFP, alpha fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CP, Child-Pugh; DNA, deoxyribonucleic acid; HBV, Hepatitis B virus; INR, international normalized ratio; PCR, polymerase chain reaction.

Figure 1  Computed tomography (CT) images taken (a) before mesenchymal stem cell infusion, showing ascites and a liver volume of 14 870 mm², and (b) at 80 weeks after infusion, showing reduced ascites and a liver volume of 20 270 mm². (c) Coronal CT view before treatment showing a huge amount of ascites and a liver volume of 8780 mm². (d) Coronal CT view at 80 weeks after treatment showing improved ascites and a liver volume of 14 640 mm². Images with largest liver volumes were chosen for the CT images.
that liver hepatocytes offer a more realistic potential source of hepatic regeneration and that various trophic factors secreted by MSCs play key therapeutic roles by influencing the activities of hepatocytes as MSCs are known to express trophic factors that reduce inflammation, apoptosis, and fibrosis of damaged tissues and stimulate angiogenesis and tissue cell regeneration.

Causes of LC also require consideration. Many studies have targeted alcoholic LC, and because alcohol is not permitted in these patients, few factors meaningfully affect study results and introduce bias. However, when studying the therapeutic effects of MSCs in patients with LC of viral origin, patients who do not take antiviral agents are preferred, but these patients are far more difficult to enroll than patients with alcoholic LC. For this reason, the number of studies on LC of viral origin is smaller than studies on alcoholic LC. Terai et al.5 conducted a study on the effect of stem cells in patients with LC of HBV or hepatitis C virus (HCV) origin. Eight of the nine patients enrolled had LC of viral origin and received antiviral agents and diuretics. The authors reported improvements in serum albumin, CP score, and alpha fetoprotein. Salama et al.2 conducted a study on the effect of autologous MSC infusion delivered via the peripheral vein in patients with LC of HCV origin. The authors reported improvements in serum albumin, INR, AST, and ALT. In our patient, AST, ALT, albumin, total bilirubin, INR, creatinine, alpha fetoprotein, quantitative HBV DNA PCR results, and CP score were improved, and improvements in clinical features such as ascites and pitting edema were remarkable after two infusions of MSCs.

The major limitation of this case report is that this patient received an antiviral agent concomitantly. However, we consider our experiences meaningful because CT after two administrations of MSCs showed an increase in hepatic volume, reduced nodularity, and loss of ascites. In addition, after two MSC infusions, the clinical symptoms and biochemical test results improved. Our observations suggest that MSCs might meaningfully increase liver volume and improve liver function in a background of LC. The majority of studies undertaken to assess the effectiveness of MSC implantation in LC patients have used biochemical tests and pathologic reports to assess outcomes rather than radiologic findings to assess liver volume. We hope that the present case study encourages the additional use of radiological findings to clarify the effects of MSCs on liver volume.

References
1 Sakaida I. Autologous bone marrow cell infusion therapy for liver cirrhosis. J. Gastroenterol. Hepatol. 2008; 23: 1349–53.
2 Salama H, Zekri AR, Medhat E et al. Peripheral vein infusion of autologous mesenchymal stem cells in Egyptian HCV-positive patients with end-stage liver disease. Stem Cell Res. Ther. 2014; 5: 70.
3 Song YM, Lian CH, Wu CS, Ji AF, Xiang JJ, Wang XY. Effects of bone marrow-derived mesenchymal stem cells transplanted via the portal vein or tail vein on liver injury in rats with liver cirrhosis. Exp. Ther. Med. 2015; 9: 1292–8.
4 Rajaram R, Subramani B, Abdullah BJJ, Mahadeva S. Mesenchymal stem cell therapy for advanced liver cirrhosis: a case report. JGH Open 2017; 1: 153–5.
5 Zekri AR, Salama H, Medhat E et al. The impact of repeated autologous infusion of haematopoietic stem cells in patients with liver insufficiency. Stem Cell Res. Ther. 2015; 6: 118.
6 Furst G, Schulte am Esch J, Poll LW et al. Portal vein embolization and autologous CD133+ bone marrow stem cells for liver regeneration: initial experience. *Radiology*. 2007; 243: 171–9.

7 Eom YW, Shim KY, Baik SK. Mesenchymal stem cell therapy for liver fibrosis. *Korean J. Intern. Med.* 2015; 30: 580–9.

8 Forbes SJ, Newsome PN. New horizons for stem cell therapy in liver disease. *J. Hepatol.* 2012; 56: 496–9.

9 Terai S, Ishikawa T, Omori K et al. Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. *Stem Cells*. 2006; 24: 2292–8.